ATLANTA, April 25, 2024 -- SweetWater Brewing Company (“SweetWater Brewing” or “SweetWater”), the largest craft brewer in the Southeast and a subsidiary of Tilray Brands, Inc., (NASDAQ: TLRY and TSX: TLRY), today announced a design refresh to make the Sweetwater brand more impactful, cohesive, and memorable to consumers. SweetWater’s upda... Read More...
VANCOUVER, British Columbia, Jan. 19, 2024 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Health Canada licensed drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, is pleased to announce it has been granted an amendment to its H... Read More...
Psyence Group Inc.TORONTO, Jan. 16, 2024 -- Psyence Group Inc ("Psyence Group") (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, today announced that its subsidiary, Psyence Biomedical Ltd ("Pubco"), has entered into a definitive securities purc... Read More...
Revive Therapeutics Ltd.TORONTO, Jan. 10, 2024 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has completed the formulation devel... Read More...
12-month data confirming that L-130 is the first reported stable oral psilocinFirst-in-Man clinical data demonstrates the superior PK profile of L-1302023 sales of $1.1M (CAD) for Altemia®VANCOUVER, British Columbia, January 08, 2024--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe"), a biopharmaceutical company focu... Read More...
- Intravenous ("IV") CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT, suggesting potential as a short-acting, scalable treatment -- Intramuscular ("IM") dosing of SPL028 produced robust, short-duration psychedelic effects in the majority of participants -- Both IV and IM routes were saf... Read More...
Silo Pharma, Inc.Final validation report expected in first quarter 2024ENGLEWOOD CLIFFS, NJ, Jan. 04, 2024 -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today provided an update on its previously announce... Read More...
- Recently announced positive Phase 2 topline data in Major Depressive Disorder ("MDD") with 79% of patients in remission from depression after two doses of CYB003 (12mg) -- Programs supported by robust intellectual property portfolio with 40 granted patents and over 170 pending applications -- Multinational operations support scaling to ... Read More...
Optimi Health Corp.VANCOUVER, British Columbia, Jan. 03, 2024 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a Health Canada licensed drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, proudly announces a significant milestone in the granting of i... Read More...
Silo dosage and time-release formulation aim for potential first at-home Ketamine therapeutic SARASOTA, FL, Dec. 28, 2023 -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced an update on its do... Read More...
TORONTO, Dec. 20, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the results of its annual general and special meeting of shareholde... Read More...
Revive Therapeutics Ltd.TORONTO, Dec. 18, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has signed a collaboration agreemen... Read More...
VANCOUVER, British Columbia, Dec. 18, 2023 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a forefront biotechnology company dedicated to revolutionising mental health and addiction treatment, proudly announces the Company has received the issuance of a Notice of Allowance by... Read More...
VANCOUVER, BC, Dec. 15, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is proud to announce that its research site, Cedar Clinical Research (CCR), has bee... Read More...
VANCOUVER, BC, Dec. 13, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, congratulates the Multidisciplinary Association of Psychedelics Studies ("MAPS" or "MAPS PBC") for its submission of a new drug a... Read More...
Red Light Holland's natural psilocybin microdosing capsules developed from psilocybin truffles grown in the company's farm in The Netherlands, have received the results of five months stability tests for the capsules, confirming stability of psilocybin.Confirmation of stability of psilocybin, at five months, follows the previously announc... Read More...
Phase 1 results show significantly increased bioavailability for its stable psilocin compared to psilocybinL-130 Phase 2 Trial Planned for 2024VANCOUVER, British Columbia, December 07, 2023--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe"), a biopharmaceutical company focused on developing transformative medicines t... Read More...
VANCOUVER, British Columbia, Dec. 07, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a licensed Canadian drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, today announced the signing of a supply agreement with Sunshine Earth Labs Ltd. (“Suns... Read More...
L-130 passes 12 months ongoing stabilityVANCOUVER, British Columbia, December 05, 2023--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the Company’s lead clinical asset, L-130, a proprietary stabilize... Read More...
- Rapid, robust, and clinically significant reduction of depression symptoms observed after a single dose of CYB003, with a clear incremental benefit of a second dose -- Primary efficacy endpoint achieved with an impressive mean -14 point difference in Montgomery-Asberg Depression Rating Scale ("MADRS") score reduction from baseline betwe... Read More...
Cash balance of $16.4 million as at September 30, 2023Revenue of $1.0 million (vs 2022: $0.7 million, an increase of 33.5%)Gross profit of $0.4 million (vs 2022: $0.3 million, an increase of 20.0%)Property, plant and equipment value of $5.1 millionTotal assets of $28.2 millionToronto, Ontario--(Newsfile Corp. - November 29, 2023) - Red Li... Read More...
DENVER, Nov. 28, 2023 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, wishes to clarify certain statement... Read More...
VANCOUVER, British Columbia, Nov. 28, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health Canada, has reached a significant milestone in its mission. The company is proud to announce the successful harvest of eight new natural Psilocybin genetics, streng... Read More...
MedSpray’s patented nose-to-brain intranasal technology selected for SPC-15 drug delivery Exclusivity covers multiple indications including anxiety disorders, Alzheimer’s disease, and anorexia ENGLEWOOD CLIFFS, NJ, Nov. 21, 2023 -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company ... Read More...
- Company to share topline Phase 2 safety and efficacy data for CYB003, its deuterated psilocybin analog being developed for the treatment of major depressive disorder -TORONTO, November 16, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to... Read More...
TORONTO, Nov. 15, 2023 -- Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), and Newcourt Acquisition Corp (Nasdaq: NCAC) (“Newcourt”), a special purpose acquisition company today announced that the registration stat... Read More...
VANCOUVER, British Columbia, Nov. 15, 2023 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that its patent application for BETR-001 and LSD d... Read More...
TORONTO, November 14, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that it has closed its previous... Read More...
Toronto, Ontario--(Newsfile Corp. - November 14, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland"), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium brand of psilocybin truffles to the legal, recreati... Read More...
Red Light Holland's natural psilocybin microdosing capsules developed from psilocybin truffles grown in the Company's farm in The Netherlands, have received the results of four months stability tests for the capsules, confirming stability of psilocybin.Confirmation of stability of psilocybin, at four months, follows the previously announc... Read More...
TORONTO, November 10, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce a firm commitment underwritten ... Read More...
VANCOUVER, British Columbia, Nov. 10, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi") is pleased to announce the successful resolution of a dispute that arose in connection with a termination notice related to a supply agreement ("the Supply Agreement") signed with a private entity on May 4, 2023. Optimi is pl... Read More...
ENGLEWOOD CLIFFS, NJ, Nov. 08, 2023 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a dose-ranging study of its targeted prophylactic treatment SPC-15 for the treatment of post-traum... Read More...
VANCOUVER, British Columbia, Nov. 07, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Canadian psychedelics drug research and formulation company, is delighted to announce the appointment of Dr. Preston A. Chase as the Company’s Chief Science Officer (“CSO”). Dr. Chase is a distinguished Research & Develop... Read More...
Potential world-first patented biomarker for long COVID Evaluating diagnostic companion with Bucillamine for long COVID TORONTO, Nov. 06, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medi... Read More...
Toronto, Ontario--(Newsfile Corp. - November 3, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilo... Read More...
Toronto, Ontario--(Newsfile Corp. - November 2, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilo... Read More...
Optimi Health Corp.VANCOUVER, British Columbia, Nov. 02, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian drug research and formulation company licensed by Health Canada to manufacture psychedelic substances such as MDMA and high-quality, GMP-grade natural psilocybin, is plea... Read More...
- Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression Rating Scale ("MADRS") score reduction from baseline between CYB003 (12mg) vs. placebo (p= 0.0005) -- For reference, pooled data from 232... Read More...
- Company to host conference call to discuss positive Phase 2 CYB003 interim results today, November 1, 2023 at 11:00 a.m. ET -- Complete Phase 2 topline data for CYB003 in MDD expected in Q4 2023 -TORONTO, November 01, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharma... Read More...
